Vapotherm, a manufacturer of noninvasive technologies for respiratory therapy, has received approval from Health Canada's Medical Device Bureau for the Precision Flow Heliox device to treat chronic lung and acute breathing disorders.
Vapotherm’s Precision Flow Heliox is developed with a modular design concept to allow for several specialty applications in neonatal, pediatric and adult patient populations.
The application assists the Precision Flow Heliox to optimize the delivery of gases via precise blending, flow control and temperature management.
Vapotherm said to expand High Flow Therapy (HFT) beyond air and oxygen to other medical and specialty gases it has created High Flow Specialty Gas Program.
Vapotherm HFT respiratory products are suppored via a simple nasal cannula in a device that is easy for clinicians to operate but comprehensive in terms of safety and performance features.
The company has also submitted for 510(k) clearance of the device in the US and for CE marking in the EU.